we didn't see quantitative changes in those markers. I did want to mention though that,
and this is very speculative of course, but some of the substrates of DPP-4 have been
hypothesized to have cardioprotective effects and those substrates would include GLP-1,
stromal cell derived factor-1 and perhaps even RANTES. I think that that's very
speculative, the bottom line is to really properly assess as we intend to do a properly
sized randomized control to really address the question directly.
you mentioned about the hypothesis generating aspects of the data whether you looked at
the various pooled analyses of primary MACE or custom MACE, it seems to be on a
favorable side, obviously the hypothesis generating for which you are going to be testing
in your upcoming outcome trial, and I wanted to just ask you, can you give us any
information perhaps on any data you may have on proinflammatory markers that
potentially could explain beyond just the hemoglobin A1c, potential benefits?
DR. KONSTAM: Yeah, I have got a few questions. One is, I know this is
principally about safety, but I sort of think about safety signals relative to the incremental
DR. WOLF: We have looked at proinflammatory markers in our program,
DR. BURMAN: Thank you. Dr. Veltri?
DR. VELTRI: Yeah, this is for Bob Wolf. Bob, I was also intrigued as
DR. WOLF: You know, we haven't seen a treatment affect an HSCRP.
DR. BURMAN: Thank you, Dr. Konstam?
clinical benefit that a drug might offer relative to other things in the market and I think
the thing that one of the things you have stressed is the low potential for hypoglycemia,
and I understand the concept of it very well. I just wondered if you can help me out
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com
DR. VELTRI: I guess the question I have, have you looked at for